Five-month-old male Syrian CM hamsters (BIO TO2 strain) (n = 12) and age and sex-matched normal hamsters (BIO FIB strain) (n = 6) were obtained from Bio Breeders Inc. (Watertown, MA). All experimental protocols were approved by the Institutional Animal Care and Use Committee of Columbia University and conform to the “Guiding Principles for the Use and Care of Laboratory Animals” of the NIH and the American Physiological Society. CM hamsters were divided into 2 groups: (i) the Simvastatin (Sim) group (n = 6), which received 20 mg/kg Sim (Merck, NJ) daily by oral gavage for 6 weeks and (ii) the Untreated group (n = 6). All hamsters underwent echocardiography at baseline and serially for a 6-week period. After 6 weeks, control and CM hamsters were euthanized with 75 mg/kg sodium pentobarbital intraperitoneal injection; the hearts were removed, weighed, and LV myocardium was snap frozen in liquid nitrogen at −80°C. A piece of ventricular myocardium was also preserved in formalin for immuno-histochemistry.
Echocardiographic Assessment of Ventricular Function
The hamsters were sedated with ketamine 100 mg/kg intramuscular and serial 2-dimensional trans-thoracic echocardiograms were performed at baseline and 3-week intervals thereafter until the end of the study (ie, 6 weeks) using an Acuson Sequoia with a 13-MHz linear transducer (15L8) in a phased-array format with real-time digital acquisition, storage, and review capabilities. LV contractile function and cardiac dimensions indexed to body surface area were compared between groups. The heart was imaged in the para-sternal short axis view at the level of the papillary muscles to obtain LV wall thickness and fractional shortening, and para-sternal long axis view to measure LV systolic and diastolic volumes and ejection fraction. Three beats were averaged for each measurement. All calculations were derived using standard formulas. 19
Left Ventricular Chamber Dimensions and Wall Thickness
LV end-diastolic (LVEDD) and end-systolic (LVESD) diameters and wall thickness were measured from M-mode tracings.
Left Ventricular Mass
Left ventricular mass was calculated according to uncorrected cube assumptions using the equation:EQUATION
where 1.055 is the specific gravity of the myocardium, IVST is the inter-ventricular septal thickness, and PWT is the posterior wall thickness.
Left Ventricular Shortening Fraction
Left ventricular shortening fraction was calculated from the M-mode LV dimensions using the equation:EQUATION
Myocardial Caspase 3 Activity Assay
Left ventricular myocardium was homogenized in cell lysis buffer, centrifuged at 12,000 g, and supernatant was separated to obtain cell lysates. Caspase 3 enzyme cleaves the p-nitroaniline (pNA) labeled substrate Ac-DEVD-pNA to release pNA, which was assayed colorimetrically at an absorbance wavelength of 405 nM in assay buffer. The reaction was started by adding 5 μl of substrate to each well containing myocardial cell lysates and measuring absorbance at 10-minute intervals for an hour. Activity was expressed as slope of absorbance over time in pmol/20 μg protein/min. Activity was also measured after pre-incubation of the cell lysates with nitro-L-arginine methyl ester (L-NAME, 0.1mM/L), an inhibitor of endogenous NOS. The NO donor, S-nitroso-N-acetyl penicillamine (SNAP) was added to cell lysates to confirm the ability of exogenous NO to inhibit caspase 3 activity.
TUNEL POD Assay for Myocyte Apoptosis
Paraffin-embedded sections of LV myocardium (5-μm thick) were dewaxed, rehydrated, and permeabilized using a Proteinase K working solution. Myocyte apoptosis was detected using an in situ cell death detection kit (Roche Diagnostics, Indianapolis, IN). DNA degradation is a key biochemical event of apoptosis, resulting in cleavage of nuclear DNA into oligonucleosome-sized fragments. Terminal deoxynucleotidyl transferase (TdT) mediated d-UTP nick-end labeling (TUNEL) was used to label DNA strand breaks as an early marker of apoptosis. The fluorescent label was converted into a colorimetric signal using the TUNEL-peroxidase (POD) as a secondary detection system. DNA fragmentation was seen as brown staining of nuclei. Tissue sections were examined microscopically at 40× magnification and the apoptotic nuclei were expressed as a percentage of normal nuclei counted in a minimum of 5 low-power fields. Tissue sections incubated with TUNEL Label only solution instead of the TUNEL reaction mixture served as the negative control while those incubated with DNAse to induce DNA strand breaks just before adding the TUNEL reaction mixture served as the positive control.
Myocardial fibrosis was measured using standard trichrome staining of paraffin-embedded LV myocardial sections. The blue stained fibrosis was measured using NIH software and expressed as a percentage of total myocardial area at 400× magnification per 10 high-power fields.
Immunohistochemistry for eNOS Staining
Paraffin-embedded sections of LV myocardium were immuno-stained with monoclonal anti-human eNOS antibody using a modification of the avidin-biotin-peroxidase method. Anti-eNOS, a murine monoclonal antibody to human eNOS (1:25 dilution, Transduction Laboratories, Lexington, KY) was used as the primary antibody and biotinylated goat anti-mouse serum (1:200 dilution) was used as the secondary antibody. Myocardial capillaries with more than 50% circumferential staining of the lumen for eNOS (excluding vessels with muscular layer) were identified in tissue sections using 400× magnification. Myocardial capillary density was expressed as number of capillaries per 3 high-power fields.
Western Blots for Myocardial eNOS
Myocardial proteins were prepared and separated on SDS/polyacrylamide gel electrophoresis. Immuno-blotting was performed using a murine monoclonal antibody to human eNOS (1:2500 dilution, Transduction Laboratories, Lexington, KY). Immuno-detection was obtained using a sheep anti-mouse secondary antibody HRPO (1:2500 dilution). Autoradiography was performed at 23°C, and the blots were quantitated by densitometry.
All data were expressed as mean ± SEM. Two-way ANOVA was used to compare serial echocardiographic data between groups and unpaired Student t test was used to compare caspase activity, apoptotic nuclear density, eNOS density, and myocardial capillary density between groups. The Student-Newman-Keuls post hoc analysis was used to identify which means were different (Sigma Stat 2.03). A value of P less than 0.05 was considered statistically significant.
Cardiac Function and Remodeling
The results of echocardiography are shown in Table 1. Figures 1 and 2 show serial changes in LV function and size in individual CM hamsters. One of the six CM hamsters in each group did not have echocardiograms at every time point; therefore, their data is not shown in the figures. At baseline study, CM hamsters had lower LV shortening fraction compared with controls, higher indexed LV end-diastolic volume, a higher indexed LV mass and wall thickness, and a lower LV mass/volume ratio (P < 0.001 vs controls). Serial echocardiograms demonstrated a progressive decline in LV shortening fraction from 17 ± 1% to 9 ± 2%, P < 0.05) (Fig. 1A) and an increase in LV end-diastolic volume from 28 ± 4 to 38 ± 1 mL/m2 (Fig. 2A). In the Sim-treated hamsters, there was no deterioration in LV function or increase in LV dilatation during serial follow-up (Figs. 1B, 2B). LV mass and mass/volume ratio did not change significantly in treated and untreated CM hamsters (Fig. 3). The control hamsters demonstrated normal LV function with no significant change in LV mass, volume, or function during follow-up (see Table 1).
Myocardial Caspase 3 Activity
Caspase 3 activity was higher in the CM hamsters (2.1 ± 0.1 pmol/20μg/min) compared with controls (1.3 ± 0.7 pmol/20μg/min). In the CM hamsters, caspase 3 activity was lower in the Sim group (1.8 ± 0.3 pmol/20μg/min) compared with the untreated group (P < 0.05). NOS inhibitor, l-NAME, increased caspase 3 activity in the Sim group (2.7 ± 0.6 pmol/20μg/min, P < 0.05) but not in the untreated group (1.8 ± 0.3 pmol/20μg/min) (Fig. 4). NO donor, SNAP, caused a rapid decay in caspase 3 activity in both groups (P < 0.05).
TUNEL staining revealed a significantly higher percentage of apoptotic nuclei in the untreated CM hamster hearts compared with controls (0.107 ± 0.03% vs 0.032 ± 0.02%, P < 0.001). Sim treatment was associated with a lower percentage of apoptotic nuclei (0.072 ± 0.02%, P < 0.01) compared with untreated hamsters (Fig. 5A). Representative microscopic images of TUNEL stained myocardial sections are shown in Figure 5B.
There was gross myocardial fibrosis in the hearts from treated and untreated CM hamsters. The average percentage of fibrotic myocardium to normal myocardium was 25 ± 11% in controls (P < 0.001 from CM hamsters), 49 ± 15% in untreated CM, and 44 ± 17% in Sim-treated hamsters. The degree of fibrosis was not different between the treated and untreated animals.
Myocardial eNOS Capillary Staining
Myocardial capillary density per 3 high-power fields in untreated CM hamsters was 56 ± 11. This was not significantly different from controls (47 ± 9). Sim treatment was associated with a higher myocardial capillary density (110 ± 12) compared with both controls and untreated CM hamsters (P < 0.01) (Fig. 6A). Myocyte nuclear density was not different among the 3 groups (data not shown) suggesting that the higher myocardial capillary density in Sim-treated hamsters was not related to higher myocardial fiber density. Representative microscopic images of myocardial sections stained with eNOS are shown in Figure 6B. Myocardial total eNOS expression measured by Western blot was not different between the 3 groups. (Representative blots are shown in Figure 6C.)
The results of our study demonstrate that Sim administration preserves myocardial function, decreases ventricular remodeling, and retards the progression of heart failure in cardiomyopathic hamsters. This may be related to an increase in myocardial capillary density in failing hearts associated with an increase in endothelial nitric oxide availability and decrease in myocardial apoptosis.
The CM hamsters develop progressive LV dilatation and heart failure secondary to a mutation in the delta-sarcoglycan protein. 16,17 In the present study, the progression of CM was characterized by LV dilatation and progressive deterioration in cardiac function during a 6-week follow-up period. Administration of Sim attenuated the progressive LV remodeling, prevented LV wall thinning and dilatation, and prevented deterioration of myocardial function compared with untreated CM hamsters. While other studies have shown the ability of statins to improve LV function and decrease LV hypertrophy, dilatation, and fibrosis following myocardial infarction, 14,15 our study is the first to show that a statin can retard the progression of heart failure in a genetic model of nonischemic CM. Previous studies by Takemoto et al 20 and Nahrendorf et al 21 demonstrated an anti-hypertrophic effect of a statin drug in isolated cardiomyocytes and in rats after myocardial infarction, respectively. In our study, Sim did not lower LV mass but prevented progressive LV thinning and dilatation thereby retarding disease progression (see Table 1). Although we did not perform blood pressure measurements, previous animal and human studies have shown no significant effect of Sim on systolic blood pressure. Therefore the effects of Sim are unlikely to be secondary to systemic hemodynamic effects. 14,22,23
The molecular mechanisms of the beneficial effects of statins in heart failure are not completely understood. Heart failure is associated with an impaired ability of the vascular endothelium to produce NO secondary to decreased eNOS expression. 5 Reduced NO contributes to increased apoptosis or programed death of myocytes. 24 Apoptosis is mediated by a family of protease enzymes called caspases. NO S-nitrosylates the active cysteine site on the enzyme, in particular caspase 3, a common downstream effector enzyme of apoptosis, to decrease apoptosis. 25 In a previous study, we demonstrated that myocardial caspase 3 activity is increased in CM hamsters secondary in part to reduced NO. 10 In the present study, baseline myocardial caspase 3 activity was higher in CM hamsters compared with controls. Sim inhibited caspase 3 activity by increasing NO bioavailability. The ability of exogenous NO to inhibit caspase 3 in both groups of CM hamsters suggests that the effect of Sim on caspase 3 was due to increase in NO availability rather than an increase in enzyme sensitivity to NO. The higher caspase activity in CM hamsters was associated with greater myocardial apoptosis. Treatment with Sim reduced myocardial apoptosis compared with untreated hamsters (Fig. 5). Therefore, reduction in apoptosis may contribute to the beneficial effects of Sim on cardiac function and remodeling.
Despite a higher myocardial mass, myocardial capillary density in untreated CM hamsters was not different compared with normal hamsters, reflecting either a failure of new blood vessel formation in response to increased myocardial mass and oxygen demand or a loss of coronary microvasculature due to the disease process. The inability of the coronary microcirculation to compensate for the increased demands of a hypertrophied and dilated myocardium may explain in part the progressive myocyte loss in CM hamsters. Our findings are consistent with the findings of other investigators who have reported reduced microvessel density in CM hearts, both ischemic and nonischemic. 26 Sim-treated hamsters, on the other hand, demonstrated a significantly higher myocardial capillary density compared with both untreated hamsters and to normal hamsters (Fig. 6). This may reflect a preservation of coronary microvasculature due to a direct vasculo-protective effect of Sim. Moreover, recent studies have demonstrated a direct angiogenic effect of Sim with reports of neo-angiogenesis in ischemic limb vasculature following treatment with Sim. 13 More recently, Taniyama et al reported increased blood flow and capillary density and reduced myocardial fibrosis in CM hamsters transfected with hepatocyte growth factor using a viral vector. 27 Studies with atorvastatin have shown a 20 to 50% increase in angiogenesis in vitro in cultured endothelial cells and in vivo in cerebral hemispheres of rats. 28,29 Our findings of increased coronary microvascular density are consistent with a possible direct angiogenic effect of Sim on new capillary formation. These findings suggest that systemic administration of a statin can mimic the effects of local gene transfection into failing hearts on new blood vessel formation and provides a novel mechanism for the benefit of statins in heart failure.
To determine if increased NO in Sim-treated hamsters was related to increased eNOS expression, we performed Western blots for eNOS on myocardial isolates. Total eNOS expression was not different between the groups. This result is not unexpected. Some investigators have demonstrated that Sim can up-regulate vascular eNOS expression secondary to a post-transcriptional increase in eNOS mRNA stability due to changes in isoprenoid synthesis. 30 Other papers report that Sim can also activate eNOS directly by a post-translational mechanism. Kureishi et al 13 reported the ability of a statin drug to phosphorylate eNOS through increased activity of phospho-kinase B or Akt in human saphenous vein endothelial cells. The downstream effects of this activation included enhanced endothelial cell survival and angiogenesis. 13 Although we did not measure phosphorylated eNOS in the hamster hearts, the ability of Sim to increase NO without an increase in eNOS expression suggests that Sim likely increases eNOS phosphorylation through a post-translational mechanism. We and other investigators have previously shown that the effect of Sim on NO production is independent of lipid lowering. 11,12
Although caution should be exercised when extrapolating results obtained from animal studies to the clinical setting, our data suggests that statins may have therapeutic implications in heart failure. Earlier studies have demonstrated that Sim reduces the incidence of heart failure in patients with coronary artery disease. 31,32 This may be in large part due to a reduction in recurrent coronary events and also a beneficial effect on LV remodeling. The findings of our study highlight the need for clinical trials in humans to prospectively evaluate the benefits of statins in heart failure. Reduced eNOS expression in heart failure limits the efficacy of drugs like ACE inhibitors whose effects are partly NO-mediated. The concurrent use of Sim may increase the efficacy of these drugs by increasing eNOS activation. 33
This study did not evaluate a survival effect of Sim in the CM hamsters. Additional prospective long-term studies are needed to determine if Sim's beneficial effects on cardiac function and remodeling translate into improved survival in heart failure and to determine if the effects of Sim represent a class effect or are unique to Sim. This is important in the context of a recent study by Marz et al 34 who showed that lovastatin and pravastatin did not alter survival in male CM hamsters. In fact, lovastatin reduced survival in female CM hamsters, the mechanism of which was not clear. 34
The statin dose used in this study is high compared with that used in the clinical setting. This dose was selected based on a study by Endres et al 1 who reported a dose-dependent increase in vascular eNOS expression and stroke protection in mice treated with 0.2, 2, and 20 mg/kg/d Sim with the largest effect seen with the highest dose. The use of a high dose allowed us to see a biologic effect within a relatively short duration of follow-up. We and other investigators have used these doses of Sim in animal studies without any adverse effects. 1,12,33 Although we did not measure liver enzymes or muscle enzymes, we found no clinical evidence of adverse or toxic clinical effects during Sim treatment. The hamsters continued to demonstrate adequate weight gain with good appetite and activity level throughout the study period.
A cause-and-effect relationship showing that the beneficial effects of Sim on remodeling were NO-related was not conclusively demonstrated in this study. The remodeling effects occurred in association with an increase in myocardial capillary eNOS staining. We plan to perform future studies to determine if administration of the NOS inhibitor, l-NAME, can prevent the effects of Sim to confirm the role of NO in this process.
We did not perform studies using CD31 or bromo-deoxyuridine to determine if the increased microvascular density represented true neo-angiogenesis. However, the finding that microvessel density in Sim treated hamsters was higher than both untreated CM hamsters and controls supports the notion of new blood vessel formation.
In conclusion, simvastatin, an HMG-CoA reductase inhibitor, can attenuate cardiac remodeling in heart failure. By virtue of its ability to up-regulate eNOS, simvastatin can reduce cardiomyocyte apoptosis and preserve myocardial function, thus retarding the progression of heart failure. Randomized clinical trials, specifically designed to assess the effects of statins on the morbidity and mortality in heart failure patients may prove statins to be an important drug in the armamentarium used to treat heart failure.
1. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Nat Acad Sci. 1998; 95:8880–8885.
2. Lefer AM, Campbell B, Shin Y-K, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999; 100:178–184.
3. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999; 19:2894–2900.
4. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995; 96:60–68.
5. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990; 81:772–779.
6. Drexler H. Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res. 1999; 43:572–579.
7. Smith CJ, Sun D, Hoegler C, et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res. 1996; 78:58–64.
8. Kuoppala A, Shiota N, Kokkonen JO, et al. Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J Am Coll Cardiol. 2002; 40:119–125.
9. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997; 336:1131–1141.
10. Mital S, Barbone A, Addonizio LJ, et al. Endogenous endothelium-derived nitric oxide inhibits myocardial caspase activity: implications for treatment of end-stage heart failure. J Heart Lung Transplant. 2002; 21:576–585.
11. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97:1129–1135.
12. Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol. 2000; 279:H2649–H2657.
13. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6:1004–1010.
14. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001; 104:982–985.
15. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002; 105:868–873.
16. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta -sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated (∼glycoprotein”) complex. PNAS. 1997; 94:13873–13878.
17. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet. 1997; 6:601–607.
18. Crespo MJAP, Escobales N. Altered vascular function in early stages of heart failure in hamsters. J Card Fail. 1997; 3:311–318.
19. Suehiro K, Takuma S, Cardinale C, et al. Assessment of segmental wall motion abnormalities using contrast two-dimensional echocardiography in awake mice. Am J Physiol Heart Circ Physiol. 2001; 280:H1729–H1735.
20. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001; 108:1429–1437.
21. Nahrendorf M, Hu K, Hiller K-H, et al. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: An experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol. 2002; 40:1695–1700.
22. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000; 35:549–555.
23. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000; 30:980–987.
24. Weiland U, Haendeler J, Ihling C, et al. Inhibition of endogenous nitric oxide synthase potentiates ischemia-reperfusion-induced myocardial apoptosis via a caspase-3 dependent pathway. Cardiovasc Res. 2000; 45:671–678.
25. Rossig L, Fichtlscherer B, Breitschopf K, et al. Nitric oxide inhibits Caspase-3 by S-Nitrosation in vivo. J Biol Chem. 1999; 274:6823–6826.
26. Liu PP, Mak S. Potential role of the microvasculature in progression of heart failure. Am J Cardiol. 1999; 84:23L–26L.
27. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension. 2002; 40:47–53.
28. Chen JZZ, Li Y, Wang Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003; 53:743–751.
29. Urbich C, Dernbach E, Zeiher AM, et al. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002; 90:737–744.
30. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998; 273:24266–24271.
31. Kjekshus J. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995; 76:64C–68C.
32. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997; 3:249–254.
33. Mital S, Magneson A, Loke KE, et al. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol. 2000; 36:248–254.
34. Marz Sr, W Muller HM, Wieland H, et al. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther. 2000; 5:275–279.